Mechanics at First Contact: Optics11 Raises $42M to Unlock the Secrets of Biomaterials

We are thrilled to announce that Optics11 has successfully raised $42,000,000 in our latest funding round, marking a significant milestone in our journey to revolutionize the field of mechanobiology.

Founded in 2011 with a vision to unlock the power of mechanobiology, our company has consistently delivered innovative solutions that enable real-time, non-destructive, mechanical characterization of soft and living biomaterials—including cells, hydrogels, spheroids, organoids, and tissues.

Our groundbreaking technology provides invaluable insights into the biological mechanics that influence both healthy and diseased cells, opening new frontiers in disease modeling, therapy development, and regenerative medicine.

This new capital injection will empower us to further refine and expand our comprehensive suite of solutions designed to seamlessly integrate into advanced laboratories worldwide.

Our pioneering products include PIUMA, a benchtop system for large tissue characterization, CHIARO, a microscope-compatible system for small tissue measurements, PAVONE, our screening-scale platform that combines automated indentation mapping with bright-field and fluorescence imaging, and CUORE, our automated contractility assay that supports the growth and monitoring of musculoskeletal tissues.

With the fresh funding, we plan to accelerate research and development, broaden our market reach, and deepen collaborations with leading experts in biomedical and clinical fields, ensuring our technology continues to drive advancements in understanding how mechanics influence biological functions.

At Optics11, mechanics truly start the moment cells are placed on the wellplate, and with this investment, we are excited to further our mission in transforming scientific research and improving patient outcomes around the globe.